Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes
India 2025: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as “Cipla”) today announced the launch of Yurpeak® (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) — two of the country’s most pressing health challenges. Cipla has the rights to distribute and promote Yurpeak® — the second…

